The genesis of that article

Someone read my sermon?

I don't think Marc Swanepoel ever caught one of your sermons, though it appears that the two of you sing in the same choir.  I put that article together yesterday using what Marc wrote years ago after he sent it to me in response to an email I sent him inquiring about advice to avoid NAC that a CZ member had read about and asked me about.

Here is the first part of his email response to me:

A number of articles have been written by Dr Schor and others advising people against the use of NAC for cancer. This advice has more to do with a specific theory of cancer than actual cell physiology. If one believes, like 99% of oncologists, that cancer is due to the uncontrolled growth of abnormal cells (whose abnormality is caused by a range of carcinogens - see http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002267/), and that the demise of these 'abnormal' cells can be brought about by, among other things, inducing apoptosis or 'cell suicide' of these cells, then this caution against the use of NAC makes some sense. Chemo treatments that are based on this intended apoptosis, are Tarceva, Doxorubicin, Cisplatin, and many others (see http://jn.nutrition.org/content/134/11/3201S.full). Other more natural treatments that rely on this same apoptosis principle, are paw-paw extract, Graviola, Cantron, Cancell as well as various acetogenin-containing substances.  However, there are MANY theories of cancer. One of them (which makes the most sense to me) is that the body has not been designed to kill itself and that cancer is simply a mechanism that the body uses to protect cells from dying when they are under oxidative stress. As can be seen below, this 'oxidative stress' situation does not just happen randomly.

The Apoptosis/Necrosis Theory (I wrote this some time ago)

and the rest you see in the article I created, where I took the liberty of adding the subtitle about NAC being essential.  I thought that what he wrote, whenever that may have been, was very much worth publishing.